학술논문

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
Document Type
article
Source
Alzheimer's & dementia : the journal of the Alzheimer's Association. 11(12)
Subject
Alzheimer's Disease Neuroimaging Initiative
Brain
Humans
Alzheimer Disease
tau Proteins
Positron-Emission Tomography
Magnetic Resonance Imaging
Memory
Neuropsychological Tests
Genotype
Heterozygote
Adult
Aged
Aged
80 and over
Female
Male
Apolipoprotein E4
Amyloid beta-Peptides
Healthy Volunteers
Biomarkers
Cognitive Dysfunction
ADNI
APOE
Apolipoprotein E
CSF
Cerebrospinal fluid
FDG
Neuroimaging
PET
SCD
SMC
Significant memory concern
Structural magnetic resonance imaging
Subjective cognitive decline
[(18)F]Florbetapir PET
[(18)F]Fluorodeoxyglucose
[F-18] Florbetapir PET
[F-18] Fluorodeoxyglucose
and over
Geriatrics
Neurosciences
Clinical Sciences
Language
Abstract
IntroductionThis study assessed apolipoprotein E (APOE) ε4 carrier status effects on Alzheimer's disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC).MethodsCognitively normal, SMC, and early mild cognitive impairment participants from Alzheimer's Disease Neuroimaging Initiative were divided by APOE ε4 carrier status. Diagnostic and APOE effects were evaluated with emphasis on SMC. Additional analyses in SMC evaluated the effect of the interaction between APOE and [(18)F]Florbetapir amyloid positivity on CSF biomarkers.ResultsSMC ε4+ showed greater amyloid deposition than SMC ε4-, but no hypometabolism or medial temporal lobe (MTL) atrophy. SMC ε4+ showed lower amyloid beta 1-42 and higher tau/p-tau than ε4-, which was most abnormal in APOE ε4+ and cerebral amyloid positive SMC.DiscussionSMC APOE ε4+ show abnormal changes in amyloid and tau biomarkers, but no hypometabolism or MTL neurodegeneration, reflecting the at-risk nature of the SMC group and the importance of APOE in mediating this risk.